加通贝祥：首予BioNTech SE(BNTX.O)买入评级 目标价192美元

美股早盘，恐惧与贪婪指数读数为24，表明市场处在极度恐惧状态。","multimedia":{"img_url":["https://n.sinaimg.cn/zhibo/364/w1838h926/20220706/a8ca-98fe3c8b0243c94aa6816428766a84c2.png"]},"commentid":"live:finance-152-2731292:0","compere_id":0,"creator":"mingyu@staff.sina.com.cn","mender":"mingyu@staff.sina.com.cn","create_time":"2022-07-06 23:08:00","update_time":"2022-07-06 23:08:07","is_need_check":"0","check_time":"1970-01-01 08:00:01","check_status":"1","check_user":"","is_delete":0,"top_value":0,"is_focus":0,"source_content_id":"0","anchor_image_url":"","anchor":"直播员","ext":"{"stocks":[],"needPush":false,"needAIPush":false,"needCMSLink":true,"needCalender":false,"needProvince":"0","docurl":"https:\/\/finance.sina.com.cn\/7x24\/2022-07-06\/doc-imizmscv0387598.shtml","docid":"mizmscv0387598"}","old_live_cid":"0","tab":"","tag":[{"id":"5","name":"市场"}],"like_nums":0,"comment_list":{"list":[],"total":0,"thread_show":0,"qreply":0,"qreply_show":0,"show":0},"docurl":"https://finance.sina.cn/7x24/2022-07-06/detail-imizmscv0387598.d.html","rich_text_nick_to_url":[],"rich_text_nick_to_routeUri":[],"compere_info":""},{"id":2731290,"zhibo_id":152,"type":0,"rich_text":"【加通贝祥：首予BioNTech SE(BNTX.O)买入评级 目标价192美元】加通贝祥分析师William Maughan开始追踪BioNTech SE(BNTX.O)，给予买入评级和192美元的目标价。他对其估值的“绝大部分”来自于公司Comirnaty新冠疫苗项目，尽管Maughan指出，基于对加强针销量的保守看法，他对新冠疫苗在未来几年的销售估计低于共识，他对剩余的产品渠道也采取了保守的估值方法。